Some stomach cancers are “cold”: immune-based drugs barely work because the body’s defenders never arrive. This study points to a brake that may be keeping those defenders out, and shows what happened when the brake was removed.
Background Gastric cancers are classified into four molecular subtypes according to The Cancer Genome Atlas (TCGA) classification: Epstein-Barr virus-positive (EBV-positive), microsatellite instability-high (MSI-H), chromosomal instability (CIN), and genomically stable (GS). Unlike MSI-H gastric cancer, GS and CIN subtypes exhibit immunologically inert microenvironments and demonstrate minimal response to immune checkpoint blockade (ICB), necessitating novel strategies to overcome immunotherapy resistance. Methods Through weighted gene co-expression network analysis (WGCNA), we identified the E3 ubiquitin ligase TRIM6 as inversely associated with MSI-H status. TRIM6-knockout murine models and subcutaneous tumors were subjected to flow cytometry, RNA sequencing, immunoblotting, and ubiquitination assays to characterize tumorinfiltrating lymphocytes (TILs), pathway activation, and TRIM6-mediated regulation of the cGAS-STING axis. Results Hypermethylation-mediated TRIM6 downregulation distinguished MSI-H from microsatellite stable (MSS) gastric cancers. Clinically, TRIM6 expression inversely correlated with cytotoxic T lymphocyte (CTL) infiltration and anti-PD-1/PD-L1 therapeutic efficacy. Mechanistically, TRIM6 catalyzed K27-linked polyubiquitination of cGAS, triggering its proteasomal degradation and consequent suppression of the cGAS-STING pathway. TRIM6 ablation enhanced CD8+ T lymphocytes infiltration via cGAS-mediated innate immune response and synergized with antiPD-L1 therapy in MSS gastric tumors. Conclusions Our results elucidate TRIM6-mediated suppression of antitumor immunity as a novel mechanism underlying ICB resistance in MSS gastric cancer, positioning TRIM6 as both a predictive biomarker and therapeutic target for immunologically cold subtypes.
Transcript
Some stomach cancers are “cold”: immune-based drugs barely work because the body’s defenders never arrive. This study points to a brake that may be keeping those defenders out—and shows what happened when the brake was removed. Gastric cancer ranks as the fifth most frequently diagnosed malignancy and the fourth leading cause of cancer-related mortality worldwide.
That makes treatment resistance a problem measured not only in laboratory results, but in lives. Among gastric cancer subtypes, some demonstrate remarkable sensitivity to immunotherapy, while others show minimal response to immune checkpoint blockade.
The resistant tumors are described as immunologically “cold,” meaning immune defenses have little presence or effect inside them. Despite these advances, the molecular basis for immunotherapy resistance in MSS-type gastric carcinomas remains poorly understood. The central question is why some tumors stay invisible or protected even when treatment is meant to help the immune system attack.
The study identified TRIM6 as a regulator linked to this problem. Higher TRIM6 levels were associated with less killer T-cell infiltration and a poorer response to pembrolizumab therapy. The search covered more than three hundred fifty E3 ligases in three hundred seventy-four gastric-cancer patients, comparing their expression with clinical features.
That candidate was TRIM6, and the study then focused on its role in MSI and gastric-cancer immunotherapy. Here is the everyday picture: imagine a building with a fire alarm and a security guard. The alarm can call help, but a guard who keeps disabling it can leave the building quiet even when danger is present.
When TRIM6 was depleted, tumors formed from MTC cells grew more slowly in mice with intact immune systems. The suppression was weaker in nude mice, linking the effect to immune defenses. The cell alarm at the center of the study is cGAS-STING, a signaling system that detects danger inside cells and helps start an immune response.
TRIM6 significantly inhibited the signal activated through this system, while an inactive form of TRIM6 failed to do so. When TRIM6 was depleted in mouse and human gastric-cancer cells, immune-warning signals increased. Removing cGAS at the same time abolished those effects, showing that cGAS was required for the response.
The downstream signaling proteins also increased after TRIM6 removal, but that increase disappeared when cGAS was depleted. The alarm therefore depended on this specific chain of signals. Removing TRIM6 slowed tumor growth when the immune system was intact, but had little effect when it was absent.
It also made tumors more responsive to immune treatment, linking TRIM6 to how effectively the body’s defenses can fight cancer. The overall pattern was consistent: elevated TRIM6 characterized MSS gastric cancers and was linked to fewer killer T cells and poorer response to pembrolizumab therapy.
At the molecular level, TRIM6 marked cGAS for destruction, suppressing innate immune signaling. Removing TRIM6 restored cGAS stability, reactivated the cGAS-STING interferon pathway, and enhanced antitumor immunity. The resulting possibility is that targeting TRIM6 could convert immunologically cold gastric tumors into tumors more responsive to immunotherapy.
The study identifies TRIM6 as a critical negative regulator of the cGAS-STING innate immune pathway in MSS gastric tumors, revealing a potential therapeutic vulnerability. But a possible treatment is not yet an available treatment. Future research must develop TRIM6-targeted agents and evaluate their safety and combined effectiveness with immune checkpoint blockade in preclinical MSS models.
TRIM6 appears to destroy a cell alarm that calls immune cells into tumors. Removing that brake restored the alarm and made otherwise resistant gastric tumors more responsive to immune treatment, although this remains a research-stage finding.
A derivative work by Paperi · AI-generated script, voice and captions
· pages and figures unaltered
Made with Paperi.
Drop in a research PDF — get a narrated video walkthrough like this one,
with highlights that follow the narration. Free to start.
Xun Liu, Yueyao Yang, Xiufeng Zheng, Ming Liu, Gang Wang
Cancer treatment may work better when the immune system gets both a clear target and help removing the brakes that hold its attack back. In mice, that combination slowed tumors, limited spread, and improved survival.Immune checkpoint inhibitors can help some cancer patients, but many tumors barely respond. This study asks whether a muscle-injected DNA vaccine and a plasmid that produces a PD-1 antibody can work better together.
Alan‐Dine Courey‐Ghaouzi, Linn Kleberg, Zaynab Mousavian, Maximilian Julius Lautenbach, Marta Pirronello, Ganesh E. Phad, Mattias N.E. Forsell, Anna Färnert, Christopher Sundling
After malaria, some immune cells long treated as exhausted may actually be moving through a carefully ordered life cycle. The surprising part is that cells from different beginnings can end up in the same late state.Atypical B cells have often been treated as one confusing, exhausted-looking population. This study instead finds a staged differentiation path, with distinct origins converging on a shared late state.
Gehad A. Basuony, Alshaimaa Hamed, Amal M. Mahfoz, Abdel Wahab M. Mahmoud, Hala Ramadan, Magda Said Ahmed Abdeltawab
A common gut parasite may be vulnerable not only to its usual medicine, but also to a diabetes drug and onion extract. The surprise is that killing it may involve changing its energy system and its chemical surroundings.What happens when a common antiparasitic drug, a diabetes medicine, and onion extract meet Blastocystis? This study finds that all three can suppress the parasite, but they do not shift its biochemical environment in the same way.
4:05
